Phio Pharmaceuticals (Phio Pharmaceuticals) Margin of Safety % (DCF Earnings Based) : N/A (As of May. 22, 2024)

View and export this data going back to 2012. Start your Free Trial

What is Phio Pharmaceuticals Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Phio Pharmaceuticals's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

Competitive Comparison of Phio Pharmaceuticals's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, Phio Pharmaceuticals's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phio Pharmaceuticals's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's Margin of Safety % (DCF Earnings Based) falls into.

Phio Pharmaceuticals Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Phio Pharmaceuticals's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Phio Pharmaceuticals (Phio Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (NAS:PHIO) » Definitions » Margin of Safety % (DCF Earnings Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

257 Simarano Drive, Suite 101, Marlborough, MA, USA, 01752

Website

https://www.phiopharma.com

Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.

Executives

Robert J Bitterman	director	C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Robert L Ferrara	director	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Patricia A Bradford	director	UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Gerrit Dispersyn	officer: Chief Development Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
John A Barrett	officer: Chief Development Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Geert Cauwenbergh	director, officer: President and CEO	1 STULTS DRIVE, PLAINSBORO NJ 08536
Alexey Eliseev	officer: Chief Business Officer	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Jonathan E Freeman	director	257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Curtis Lockshin	director	4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
H. Paul Dorman	director	1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Opko Health, Inc.	10 percent owner	4400 BISCAYNE BLVD., MIAMI FL 33137
Advanced Rna Technologies, Llc	10 percent owner	1 KENDALL SQUARE BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Keith L Brownlie	director	777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Pamela Pavco	officer: Chief Development Officer	C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, WESTBOROUGH MA 01581
Caitlin Kontulis	officer: Secretary and Controller	1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581